Gastrin and cyclooxygenase-2(COX-2) playimportant roles in the carcinogenesis and progression ofgastric cancer.However,it remains unknown whether the combination of cholecystokinin-2(CCK-2) receptor antagonist plus CO...Gastrin and cyclooxygenase-2(COX-2) playimportant roles in the carcinogenesis and progression ofgastric cancer.However,it remains unknown whether the combination of cholecystokinin-2(CCK-2) receptor antagonist plus COX-2 inhibitor exerts synergistic anti-tumor effects on human gastric cancer.Here,we demonstrated that the combination of AG-041R(a CCK-2 receptor antagonist) plus NS-398(a selective COX-2 inhibitor) treatment had synergistic effects on proliferation inhibition,apoptosis induction,down-regulation of Bcl-2 and up-regulation of Bax expression in MKN-45 cells.These results indicate that simultaneous targeting of CCK-2 receptor and COX-2 may inhibit gastric cancer development more effectively than targeting either molecule alone.(C)2008 Elsevier Ireland Ltd.All rights reserved.展开更多
抗体药物偶联物(antibody drug conjugates,ADCs)是一类新型的抗肿瘤药物,兼具有靶向药物的特异性和化疗药物的高度抗肿瘤活性,极具临床应用前景。近年来,乳腺癌的治疗正进入ADCs治疗时代,以恩美曲妥珠单抗、德曲妥珠单抗等为代表的ADCs...抗体药物偶联物(antibody drug conjugates,ADCs)是一类新型的抗肿瘤药物,兼具有靶向药物的特异性和化疗药物的高度抗肿瘤活性,极具临床应用前景。近年来,乳腺癌的治疗正进入ADCs治疗时代,以恩美曲妥珠单抗、德曲妥珠单抗等为代表的ADCs,为人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌患者的治疗带来了新的突破。此外,ADCs的出现,引入了“HER2低表达(HER2-low)”的概念,并为HER2-low的乳腺癌患者带来了生存获益。本综述重点探讨了ADCs在治疗HER2表达乳腺癌中的应用进展。展开更多
文摘Gastrin and cyclooxygenase-2(COX-2) playimportant roles in the carcinogenesis and progression ofgastric cancer.However,it remains unknown whether the combination of cholecystokinin-2(CCK-2) receptor antagonist plus COX-2 inhibitor exerts synergistic anti-tumor effects on human gastric cancer.Here,we demonstrated that the combination of AG-041R(a CCK-2 receptor antagonist) plus NS-398(a selective COX-2 inhibitor) treatment had synergistic effects on proliferation inhibition,apoptosis induction,down-regulation of Bcl-2 and up-regulation of Bax expression in MKN-45 cells.These results indicate that simultaneous targeting of CCK-2 receptor and COX-2 may inhibit gastric cancer development more effectively than targeting either molecule alone.(C)2008 Elsevier Ireland Ltd.All rights reserved.
文摘目的探讨基于动态对比增强磁共振成像(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)和扩散加权成像(diffusion-weighted imaging,DWI)的瘤内及瘤周影像组学预测乳腺癌人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)状态的价值。材料与方法回顾性分析246例经术后病理证实的乳腺癌患者的临床及影像学资料,按7∶3比例随机分为训练组和验证组。采用ITK-SNAP软件手动勾画病灶瘤内感兴趣区,使用PHIgo-AK软件进行瘤周的扩展并提取瘤内及瘤周的影像组学特征。采用最小冗余最大相关(max-relevance and min-redundancy,mRMR)算法等选择DCE-MRI、DWI瘤内及瘤周的最优特征数。分别建立单序列及联合序列的影像组学模型,采用受试者工作特征(receiveroperating characteristic,ROC)曲线对各模型的预测效能进行分析,并计算曲线下面积(area under the curve,AUC),选出预测效能最高的模型,在训练组中从临床及常规影像学特征中通过单因素logistic回归筛选出预测HER-2状态的独立危险因素,结合预测效能最高模型的影像组学标签评分(radiomic score,rad-score)建立融合模型,并以诺模图(nomogram)展示,采用AUC值,决策曲线分析(decision curve analysis,DCA)评估模型的效能及临床价值。结果基于DCE-MRI和DWI瘤内及瘤周的影像组学联合模型预测HER-2状态的AUC值在训练组和验证组分别为0.953和0.948,效能最高。肿瘤最大径是区分乳腺癌HER-2状态的独立危险因素,最终结合rad-score和肿瘤最大径建立的融合模型对乳腺癌HER-2状态有良好的预测效能,在训练组的AUC值为0.961,验证组为0.958。结论基于DCE-MRI和DWI瘤内及瘤周的影像组学方法对乳腺癌HER-2状态的预测具有良好的价值。
